· Published by Health Canada · Official notice
September 7, 2016
For immediate release
OTTAWA - Health Canada is reminding Canadians of the serious risk of birth defects associated with taking the prescription acne drug isotretinoin while pregnant. Health professionals and women who are using, or considering using this drug are reminded of the importance of not getting pregnant while taking this treatment.
Isotretinoin, available under the brand names Accutane, Clarus and Epuris, is used to treat severe acne when other therapies have not worked. It has been available in Canada for more than 30 years.
The reminder comes in light of a recent study commissioned by Health Canada. Health Canada commissioned the study as part of ongoing work to evaluate the risk-management measures currently in place for isotretinoin. The study identified continued reports of pregnancy among patients using isotretinoin, despite the comprehensive risk management measures in place.
There is a known, high risk of birth defects if a woman gets pregnant while taking isotretinoin. This includes malformation of the limbs, head, face, heart and central nervous system of a fetus. To address this risk, Canada, like other countries, has instituted a pregnancy prevention program. Specifically, the program requires patients’ written consent, two negative pregnancy tests before starting treatment, monthly tests during treatment and one month after stopping, and the use of two reliable methods of birth control through this period.
Products are prominently labelled to warn of the risk of birth defects and the importance of actively preventing pregnancy. In addition, manufacturers provide comprehensive patient screening and monitoring tools and advice, reminders to health professionals, educational materials, which both prescribers and patients are strongly encouraged to use, and websites providing pregnancy prevention materials.
Health Canada continues to assess what additional measures may be needed. Canadians will be informed of any new steps to improve the safe use of isotretinoin.